$--
(Market cap
$6 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
2,025,200
9 Years Aggregate
CFO
$-119.36 Mln
EBITDA
$-157.82 Mln
Net Profit
$-190.40 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
First Wave BioPharma (FWBI)
| -50.7 | -30.8 | -68.3 | -93.2 | -96.1 | -87.7 | -- |
|
BSE Sensex*
| -11.9 | -3.9 | -11.5 | -6.2 | 6.4 | 8.7 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
First Wave BioPharma (FWBI)
| -96.6 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
First Wave BioPharma (FWBI)
|
2.1 | 6.0 | 0.1 | -6.2 | -15,087.2 | -15.2 | -- | 1.9 |
| 25.6 | 2,212.9 | 174.9 | -190.4 | -118.4 | -54.6 | -- | 7.0 | |
| 22.9 | 71.7 | 0.0 | -24.8 | -- | -81.5 | -- | 2.1 |
Shareholding Pattern
View DetailsAbout First Wave BioPharma (FWBI)
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include... latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida. Read more
-
CEO & Chairman
Mr. James R. Sapirstein M.B.A., R.Ph.
-
CEO & Chairman
Mr. James R. Sapirstein M.B.A., R.Ph.
-
Headquarters
Boca Raton, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for First Wave BioPharma (FWBI)
What is the current share price of First Wave BioPharma Inc (FWBI) Today?
The share price of First Wave BioPharma Inc (FWBI) is $2.07 (NASDAQ) as of 14-Jun-2024 09:30 EDT. First Wave BioPharma Inc (FWBI) has given a return of -96.13% in the last 3 years.
What is the current PB & PE ratio of First Wave BioPharma Inc (FWBI)?
Since, TTM earnings of First Wave BioPharma Inc (FWBI) is negative, P/E ratio is not available.
The P/B ratio of First Wave BioPharma Inc (FWBI) is 1.87 times as on 14-Jun-2024, a 56 discount to its peers’ median range of 4.29 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
What is the 52 Week High and Low of First Wave BioPharma Inc (FWBI)?
The 52-week high and low of First Wave BioPharma Inc (FWBI) are Rs -- and Rs -- as of 12-May-2026.
What is the market cap of First Wave BioPharma Inc (FWBI)?
First Wave BioPharma Inc (FWBI) has a market capitalisation of $ 6 Mln as on 14-Jun-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in First Wave BioPharma Inc (FWBI)?
Before investing in First Wave BioPharma Inc (FWBI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.